Although PRES is more commonly reported with VEGF-targeting monoclonal antibodies such as bevacizumab, small-molecule TKIs like sorafenib, sunitinib, and regorafenib have also been implicated [10].Fruquintinib shares a similar target profile and, although rarely reported, has now been associated with PRES in a small number of published cases. Here, VEGFA is linked to Posterior Leukoencephalopathy Syndrome.